HOUSE_OVERSIGHT_024821.jpg
1.15 MB
Extraction Summary
4
People
11
Organizations
7
Locations
2
Events
3
Relationships
3
Quotes
Document Information
Type:
Market research report / financial analysis
File Size:
1.15 MB
Summary
This Cowen report page discusses the global regulatory landscape for CBD, highlighting developments in Europe and Latin America, and analyzes the U.S. regulatory outlook following the 2018 Farm Bill. It details the shifting oversight from the DEA to the Department of Agriculture while noting continued FDA authority and regulatory uncertainty regarding CBD products.
People (4)
| Name | Role | Context |
|---|---|---|
| Azer | ||
| Eric Assaraf | ||
| Scott Gottlieb | ||
| Michael Cella |
Organizations (11)
| Name | Type | Context |
|---|---|---|
| Cowen | ||
| Cowen Washington Research Group | ||
| WHO | ||
| EU | ||
| Canopy Growth | ||
| Tilray | ||
| Aurora | ||
| Cronos | ||
| DEA | ||
| Department of Agriculture | ||
| FDA |
Timeline (2 events)
WHO evaluation of CBD
2018 Farm Bill
Locations (7)
| Location | Context |
|---|---|
Relationships (3)
Key Quotes (3)
"The 2018 Farm Bill declassifies industrial hemp as a Schedule I substance"Source
HOUSE_OVERSIGHT_024821.jpg
Quote #1
"it seems clear that there will be a period of regulatory uncertainty over CBD products at the state and federal level"Source
HOUSE_OVERSIGHT_024821.jpg
Quote #2
"In Europe, CBD products are now widely available in markets like the U.K., Italy and Switzerland"Source
HOUSE_OVERSIGHT_024821.jpg
Quote #3
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein document